

Materials and Method

Note: To our best knowledge, this should represent an accurate description of the materials and methods required to reproduce our work. If any of the content on this page is difficult to interpret or should you have trouble repeating our work, do not hesitate to [contact us](#) as soon as possible in order for us to provide additional information and advice.

Entry Clone Source: MGC

Entry Clone Accession: IMAGE:5114635

SGC Construct ID: CLK3A-c005

GenBank GI number: gi|4502885

Vector: pNIC28-Bsa4. Details [[PDF](#)]; Sequence [[FASTA](#)] or [[GenBank](#)]

Amplified construct sequence:

```
TACTTCCAATCCATGCAGAGCAGTAAGCGC
AGCAGCCGGAGTGTGGAAGATGACAAGGAG
GGTCACCTGGTGTGCCGGATCGCGATTGG
CTCCAAGAGCGATATGAGATTGTGGGGAAAC
CTGGGTGAAGGCACCTTGGCAAGGTGGT
GAGTGCTGGACCATGCCAGAGGGAAAGTCT
CAGGTTGCCCTGAAGATCATCCGCAACGTG
GGCAAGTACCGGGAGGGCTGCCCGCTAGAA
ATCAACGTGCTCAAAAAAAATCAAGGAGAAG
GACAAAGAAAACAAGTTCCTGTGTCTTG
ATGTCTGACTGGTTCAACTTCCACGGTCAC
ATGTGCATGCCCTTGAGCTCCTGGGCAAG
AACACCTTGAGTTGAAGGAGAATAAC
TTCCAGCCTTACCCCTACCACATGTCCGG
CACATGCCCTTACAGCTGTGCCACGCCCTT
AGATTTCATGAGAATCAGCTGACCCAT
ACAGACTGAAACCAGAGAACATCCTGTT
GTGAATTCTGAGTTGAACACCTCTACAAT
GAGCACAAGAGCTGTGAGGAGAAGTCAGTG
AAGAACACCAAGCATCCGAGTGGCTGACTTT
GGCAGTGCCACATTGACCATGAGCACCAC
ACCACCATGTGCCACCGTCACTATCGC
CCGCCTGAGGTGATCCTTGAGCTGGGCTGG
GCACAGCCCTGTGACGTCTGGAGCATTGGC
TGCATTCTCTTGAGTACTACCGGGGCTTC
ACACTCTCCAGACCCACGAAAACCGAGAG
CACCTGGTGTGATGGAGAACATCCTAGGG
CCCATCCCATCACACATGATCCACCGTACC
AGGAAGCAGAAATATTTCTACAAAGGGGGC
CTAGTTGGGATGAGAACAGCTGTGACGGC
CGGTATGTGAAGGAGAACTGCAAACCTCTG
AAGAGTTACATGCTCCAAGACTCCCTGGAG
CACGTGCAGCTGTTGACCTGATGAGGAGG
ATGTTAGAATTGACCCCTGCCAGCGCATC
ACACTGGCCGAGGCCCTGTCACCCCTTC
TTTGCTGGCTTGACCCCTGAGGAGCGGTCC
TTCCACACCTAAGACAGTAAAGGTGGATA
```

Final protein sequence (tag sequence in lowercase):

```
mhyyyyhssgvdlgtenlyfqSMQSSKRSS
RSVEDDKEGHHLVCRIGDWLQERYEIVGNLG
EGTGFGVVECLDHARGKSQVALKIIIRNVGK
YREAARLEINVLKKIKEKDKENKFLCVLMS
DWFNFHGHMCIAFELLGKNTFEFLKENNFO
PYPLPHVRHMYQLCHALRFLHENQLTHD
LKPNILFVNSEFETLYNEHKSEEKSVKN
TSIRVADFGSATFDHEHHTTIVATRHYRPP
```

EVILELGWAQPCDVWSIGCILFEYYRGFTL
FQTHENREHLMVMEKILGPIPSHMIHRTK
QKYFYKGGLVWDENS SDGRYVKENCKPLKS
YMLQDSLEHVQLFDLMRRMLEFDPAQRITL
AEALLHPFFAGLTPEERSFHT

Tags and additions: Tag sequence: mhhhhhhssgvdlgtenlyfq*s(m). TEV-cleavable (*) N-terminal hexaHis tag.

Host: BL21 (DE3)

Growth medium, induction protocol: 1 ml from a 10 ml overnight culture in LB, 50 µg/ml kanamycin was used to inoculate 1 litre of LB medium containing 50 µg/ml kanamycin. Cultures were grown at 37°C until they reached an OD₆₀₀ of 0.3 and then cooled to 18°C. Expression was induced for 4 hours using 1 mM IPTG at an OD₆₀₀ of 0.6. The cells were collected by centrifugation, transferred to 50 ml tubes, resuspended in 30 ml binding buffer, and frozen. Binding buffer: 50 mM HEPES pH 7.5, 500 mM NaCl, 5% Glycerol, 50 mM L-Arg and L-Glu.

Extraction buffer, extraction method: The frozen cells were thawed on ice and binding buffer (plus 1 mM PMSF) added to a final volume of 50 ml. Cells were lysed using a high pressure cell disruptor. The lysate was centrifuged at 18,500 RPM for 50 minutes and the supernatant collected for purification.

Column 1: Ion exchange - Nucleic acid removal. DEAE cellulose (DE52, Whatman), 10 g of resin in 2.5 x 20 cm column. The resin was hydrated in 2.5M NaCl, then washed with 20 ml binding buffer prior to loading the sample.

Column 1 Buffers: Binding buffer: 50 mM HEPES, 500 mM NaCl, 5% Glycerol, 50 mM L-Arg and L-Glu.

Column 1 Procedure: Supernatant was applied at gravity flow, followed by a wash with 50 ml binding buffer. The column flow-through was collected.

Column 2: Ni-affinity. Ni-NTA (Qiagen), 5 ml of 50% slurry in 1.5 x 10 cm column, washed with binding buffer.

Column 2 Buffers: Binding buffer: 50 mM HEPES pH 7.5, 500 mM NaCl, 5% Glycerol, 50 mM L-Arg and L-Glu. **Wash buffer:** 50 mM HEPES pH 7.5, 500 mM NaCl, 20 mM Imidazole, 5% glycerol, 50 mM L-Arg and L-Glu. **Elution buffer:** 50 mM HEPES pH 7.5, 500 mM NaCl, 50 to 250 mM Imidazole, 5% Glycerol, 50 mM L-Arg and L-Glu.

Column 2 Procedure: The flowthrough from column 1 was loaded by gravity flow on the Ni-NTA column. The column was then washed with 3 x 10 ml wash buffer at gravity flow. The protein was eluted by gravity flow by applying 5-ml portions of elution buffer with increasing concentration of imidazole (50 mM, 100 mM, 150 and 250 mM); fractions were collected until essentially all protein was eluted. After elution DTT was added to a final concentration of 10 mM.

Enzymatic treatment : (Dephosphorylation and His tag cleavage) Samples containing CLK3 were pooled and 20 µg GST-lambda phosphatase and 20 µg TEV protease added for overnight incubation at 4°C: protein solution contained 10 mM DTT and 0.05 mM MnCl₂. For crystallization of phosphorylated CLK3 the protein was only treated with TEV protease

Column 3: Size Exclusion Chromatography

Column 3 Buffers: Fractions containing CLK3 collected from IMAC were concentrated and directly applied to a S75 16/60 HiLoad gel filtration column equilibrated in 50 mM Hepes pH 7.5, 500 mM NaCl, 50 mM L-glutamic acid, 50 mM L-arginine.

Column 3 Procedure: AKTA-prime

Column 4: Anion Exchange Chromatography

Column 4 Buffers: Fractions containing CLK3 collected from SEC were diluted to a final concentration of 50 mM HEPES pH 7.5, 50 mM NaCl and applied to a MonoQ 5/50 GL equilibrated in 50 mM Hepes pH 7.5, 50 mM NaCl. The protein was eluted using an NaCl gradient.

Column 4 Procedure: AKTA-express

Mass spec characterization: LC- ESI -MS TOF confirmed the correct mass expected for this construct.

Intact Mass: Masses of purified proteins were confirmed by LC-MS, using an Agilent LC/MSD TOF system with reversed-phase HPLC coupled to electrospray ionisation and an orthogonal time-of-flight mass analyser. Proteins were desalted prior to mass spectrometry by rapid elution off a C3 column with a gradient of 5-95% acetonitrile in water with 0.1% formic acid.

Crystallization: Crystals were grown at 4°C in 150nl sitting drops mixing 75 nl of CLK3 11.4mg/ml in 50mM Hepes pH 7.5, 200mM NaCl, 10mM DTT, with 75 nl of a solution containing 0.2M $(\text{NH}_4)_2\text{SO}_4$; 0.1M BIS-TRIS pH 5.5; 25% PEG 3350. The inhibitors were added to the concentrated protein solution (1 mM end concentration) using a DMSO stock solution.

Data Collection: Resolution: X-ray source: Synchrotron SLS -X10, single wavelength (2wu6) and using Brucker rotating anode (Copper target) generator equipped with a CCD detector (2wu7), respectively. Crystals were cryoprotected using the crystallization solution supplemented with 25% ethylene glycol.

Note: To our best knowledge, this should represent an accurate description of the materials and methods required to reproduce our work. If any of the content on this page is difficult to interpret or should you have trouble repeating our work, do not hesitate to [contact us](#) as soon as possible in order for us to provide additional information and advice.